KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Cash: 2019-2024

Historic Change in Cash for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to $201.6 million.

  • Recursion Pharmaceuticals' Change in Cash rose 384.09% to $133.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $231.3 million, marking a year-over-year increase of 498.89%. This contributed to the annual value of $201.6 million for FY2024, which is 227.85% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Change in Cash stood at $201.6 million for FY2024, which was up 227.85% from -$157.7 million recorded in FY2023.
  • Recursion Pharmaceuticals' 5-year Change in Cash high stood at $263.8 million for FY2022, and its period low was -$157.7 million during FY2023.
  • In the last 3 years, Recursion Pharmaceuticals' Change in Cash had a median value of $201.6 million in 2024 and averaged $102.6 million.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Change in Cash skyrocketed by 835.93% in 2022 and then slumped by 159.78% in 2023.
  • Over the past 5 years, Recursion Pharmaceuticals' Change in Cash (Yearly) stood at $192.0 million in 2020, then plummeted by 85.32% to $28.2 million in 2021, then spiked by 835.93% to $263.8 million in 2022, then slumped by 159.78% to -$157.7 million in 2023, then spiked by 227.85% to $201.6 million in 2024.